Safety of Hydroxychloroquine: What a Dermatologist Should Know
- PMID: 39899183
- PMCID: PMC11850461
- DOI: 10.1007/s40257-025-00919-x
Safety of Hydroxychloroquine: What a Dermatologist Should Know
Abstract
The unique immunomodulatory properties of hydroxychloroquine (HCQ) have attracted considerable interest beyond its use for malaria and rheumatological diseases, including a variety of dermatological conditions. Over recent years, especially after the coronavirus disease 2019 (COVID-19) pandemic, the prescription of HCQ has also significantly expanded, sometimes inappropriately, thus posing additional challenges on its optimal use, due to emerging safety issues. In this review, we provide dermatologists with the latest advancements on selected clinically relevant toxicities, namely retinopathy, pro-arrhythmia, cutaneous reactions, and neuropsychiatric effects. It is hoped this update can assist dermatologists to identify high-risk patients for tailored monitoring, screening, and risk minimization strategies, thus supporting safer HCQ prescribing.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Funding: Open access funding provided by Alma Mater Studiorum - Università di Bologna within the CRUI-CARE Agreement. Authors' Contributions: All authors participated equally in the drafting of the manuscript. All authors read and approved the final paper. Conflict of Interest: All authors have no relevant financial or non-financial interests to disclose. Ethics Approval; Patient Consent: Not applicable. Code Availability: Not applicable. Data availability: Not applicable.
Figures
References
-
- Stokkermans TJ, Falkowitz DM, Trichonas G. Chloroquine and Hydroxychloroquine Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Sep 8]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK537086/. Accessed 8 Sep 2024 - PubMed
-
- US prescribing information: Plaquenil [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/009768s054lbl.pdf. Accessed 8 Sep 2024
-
- go.drugbank.com: Hydroxychloroquine. [Internet]. [cited 2024 Sep 8]. Available from: https://go.drugbank.com/drugs/DB01611. Accessed 8 Sep 2024
-
- Paludetto MN, Kurkela M, Kahma H, Backman JT, Niemi M, Filppula AM. Hydroxychloroquine is metabolized by cytochrome P450 2D6, 3A4, and 2C8, and inhibits cytochrome P450 2D6, while its metabolites also inhibit cytochrome P450 3A in vitro. Drug Metab Dispos. 2023;51(3):293–305. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
